RESUMEN
Purpose: While the pivotal role of pharmacotherapy in psychiatry is universal, significant regional differences exist in drug use patterns. Herewith we compare the use of ATC psychotropic drugs (N05, psycholeptics and N06A, antidepressants) in 2010-2015 in the three Baltic Countries with reference to the Nordic Countries.Methods: Data were obtained from the national authorities on medicines as expressed in DDD per 1000 inhabitants per day. A semi-structured questionnaire was used for expert statements on the rationale of current use of medicines.Results: During the observation period the use of antipsychotics, anxiolytics, hypnotics and sedatives, and antidepressants steadily increased, while the growth in use of anxiolytics stagnated in the more recent years. Antipsychotic use was the largest in Lithuania and the lowest in Estonia. The use on anxiolytics in Lithuania was more than twice of that in Estonia and Latvia. Conversely, the use of hypnotics and sedatives was about three times higher in Estonia than in Latvia or Lithuania. Antidepressant use was dominated by the selective serotonin reuptake inhibitors in all three countries, but overall was much lower in Latvia as compared to Lithuania and Estonia. As compared to the Nordic Countries in 2015, antidepressants are used at much lower level throughout Baltics, probably reflecting underdiagnostics of depression and anxiety disorders.Conclusion: While the health-care expenditures in Estonia, Latvia and Lithuania are largely similar, as is the cultural and recent political background of these EU member countries, the extent and the pattern of psychotropic drug use is remarkably variable.
Asunto(s)
Trastornos Mentales/tratamiento farmacológico , Psicotrópicos/uso terapéutico , Encuestas y Cuestionarios , Estonia/epidemiología , Humanos , Letonia/epidemiología , Lituania/epidemiología , Masculino , Trastornos Mentales/economía , Trastornos Mentales/epidemiología , Psicotrópicos/economía , Países Escandinavos y Nórdicos/epidemiologíaRESUMEN
BACKGROUND: While there is close contact established between Latvia and the Nordic psychiatric community now, there are many pages of our history we have not had opportunity to share. The aim of this article is to highlight the most important facts of more than 200 years of history of psychiatry in Latvia. RESULTS: The development of the psychiatric services in Latvia started with the building of an asylum-type establishment at the end of the 1700s. To address the increasing needs, psychiatric hospitals of various size and quality were gradually opened all over the country. Psychiatry as a field of science emerged in Latvia after the Declaration of Independence in 1918. Active and progressive development of services and the academic environment took place between the World Wars. During the Soviet regime, psychiatric services were rebuilt within the frameworks and guidelines of the existing system. Following the restoration of Independence in 1991, a number of rapid and positive changes took place. There was a gradual decrease in the number of hospital beds, outpatient services were developed and modern treatment methods were established. Policy documents in the field of mental health were developed and legislation improved. Active collaboration with other, particularly Scandinavian, countries was developed. Academic education continued and specialist training was provided following European standards. The role of the psychiatric professional organization was strengthened. CONCLUSIONS: Many positive changes in the mental healthcare in Latvia have taken place, but there are still some aspects to be addressed. The strengthening of our regional collaboration could be crucial for our future development.
Asunto(s)
Trastornos Mentales/terapia , Psiquiatría/historia , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Hospitales Psiquiátricos/historia , Humanos , Letonia , Servicios de Salud Mental/historia , Condiciones Sociales , Segunda Guerra MundialRESUMEN
BACKGROUND: A distinctive extrapyramidal syndrome has been observed in intravenous methcathinone (ephedrone) users in Eastern Europe and Russia. METHODS: We studied 23 adults in Latvia who had extrapyramidal symptoms and who had injected methcathinone for a mean (+/-SD) of 6.7+/-5.1 years. The methcathinone was manufactured under home conditions by potassium permanganate oxidation of ephedrine or pseudoephedrine. All patients were positive for hepatitis C virus, and 20 were also positive for the human immunodeficiency virus (HIV). RESULTS: The patients reported that the onset of their first neurologic symptoms (gait disturbance in 20 and hypophonia in 3) occurred after a mean of 5.8+/-4.5 years of methcathinone use. At the time of neurologic evaluation, all 23 patients had gait disturbance and difficulty walking backward; 11 patients were falling daily, and 1 of these patients used a wheelchair. Twenty-one patients had hypophonic speech in addition to gait disturbance, and one of these patients was mute. No patient reported decline in cognitive function. T(1)-weighted magnetic resonance imaging (MRI) showed symmetric hyperintensity in the globus pallidus and in the substantia nigra and innominata in all 10 active methcathinone users. Among the 13 former users (2 to 6 years had passed since the last use), lesser degrees of change in the MRI signal were noted. Whole-blood manganese levels (normal level, <209 nmol per liter) averaged 831 nmol per liter (range, 201 to 2102) in the active methcathinone users and 346 nmol per liter (range, 114 to 727) in former users. The neurologic deficits did not resolve after patients discontinued methcathinone use. CONCLUSIONS: Our observation of a distinctive extrapyramidal syndrome, changes in the MRI signal in the basal ganglia, and elevated blood manganese levels in methcathinone users suggests that manganese in the methcathinone solution causes a persistent neurologic disorder.